Skip to main content
Charlene Mantia, MD, Oncology, Boston, MA

CharleneMantiaMD

Oncology Boston, MA

Medical Oncologist at Dana-Farber Cancer Institute

Dr. Mantia is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Mantia's full profile

Already have an account?

  • Office

    450 Brookline Ave
    Boston, MA 02215
    Phone+1 617-632-6328
    Fax+1 617-632-2165

Education & Training

  • Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2017 - 2020
  • Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2014 - 2017
  • Albany Medical College
    Albany Medical CollegeClass of 2014

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2014 - 2026
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell Carcinoma  
    Praful Ravi, Charlene Mantia, Christopher Su, Neeraj Agarwal, Yousef Zakharia, Rana R Mckay, Vivek Narayan, Ajjai Alva, Bradley A Mcgregor, David F Mcdermott, Toni K C..., JAMA Oncology

Abstracts/Posters

  • Recurrent Intracranial Hemorrhage and Venous Thromboembolism Following Initial Intracranial Hemorrhage in Patients with Brain Tumors on Anticoagulation
    Charlene Mantia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

  • Sensitivity of treatment-free survival (TFS), a novel outcome, to subgroup analyses of patients (pts) with advanced melanoma (MEL) treated with immune checkpoint inhib... 
    2019 ASCO Annual Meeting - 6/1/2019

Authored Content

  • Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020
  • Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020